Craft

NexImmune

Stock Price

$3.6

2024-05-07

Market Capitalization

$4.9 M

2024-05-07

NexImmune Summary

Company Summary

Overview
NexImmune is a biopharmaceutical company developing immunotherapy products based on the Artificial Immune Modulation nanotechnology platform. The company focuses on products that help cure cancer by directing T cell function to restore natural immunity.
Type
Public
Status
Active
Founded
2011
HQ
Gaithersburg, MD, US | view all locations
Website
https://www.neximmune.com/
Cybersecurity rating
Sectors

Key People

  • Kristi Jones

    Kristi Jones, Chief Executive Officer, Director

  • John Trainer

    John Trainer, Chief Financial Officer

  • Bob Knight

    Bob Knight, Chief Medical Officer

    • Daniel Bednárik

      Daniel Bednárik, Senior Vice President, Molecular Engineering and Protein Design

    Operating MetricsView all

    Discovery Phase Products

    1

    Feb, 2021

    Preclinical Phase Products

    3

    Feb, 2021

    Phase I Trials Products

    2

    Feb, 2021

    LocationsView all

    1 location detected

    • Gaithersburg, MD HQ

      United States

      9119 Gaither Rd

    NexImmune Financials

    Summary Financials

    Net income (FY, 2023)
    ($32.3M)
    Cash (FY, 2023)
    $3.2M
    EBIT (FY, 2023)
    ($33.0M)

    Footer menu